United States Anti-Obesity Drugs Market Sector 2025: Pfizer's acquire $10B Metsera Tug of War & Novo Nordisk's Akero Acquisition

Global Anti-Obesity Drugs Market reached US$ 2.5 billion in 2022 and is expected to reach US$ 43.7 billion by 2030 growing with a CAGR of 45.5% during the forecast period 2024-2031.

DataM Intelligence has released its latest report on the "Anti-obesity Drugs Market Size 2025," providing a detailed analysis of market trends, key growth drivers, competitive landscape, and regional insights. The report includes market size (value and volume), CAGR projections, and emerging opportunities that help businesses identify growth areas and build effective strategies. Backed by data-driven insights and future outlook, this study serves as a valuable resource for companies looking to stay competitive and capitalize on market potential.

Innovent Biologics (Suzhou) Co. Ltd., a clinical-stage biopharmaceutical company focused on anti-obesity drugs, announced topline results from its Phase II trial (NCT04904913) of IBI362, a dual GLP-1 and glucagon receptor agonist, for obesity treatment in China.

North America is projected to capture around 38.3% of the market share by 2030, driven by the region's increasing obese population.

Latest M&A

Pfizer acquired Metsera in a $10 billion deal in 2025, adding next-generation anti-obesity drugs with oral and injectable incretin and amylin agonist therapies to its pipeline, outbidding Novo Nordisk.​

Novo Nordisk acquired Akero Therapeutics for $5.2 billion, enhancing its portfolio with the FGF21 analog efruxifermin, targeting MASH and obesity-related metabolic disorders.​

Other biotech-focused acquisitions increased investment into emerging GLP-1, dual/triple agonist, and non-GLP obesity therapeutics.​

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://datamintelligence.com/download-sample/anti-obesity-drugs-market?kb

Key Player:

Eli Lilly and Company, Bayer AG, Bristol-Myers Squibb, Currax Pharmaceuticals LLC, F. Hoffmann-La Roche AG, GlaxoSmithKline PLC, Merck & Co. Inc., Norgine BV, Novo Nordisk AS, and Pfizer Inc.,

Latest News & Drug Pipeline

Eli Lilly's tirzepatide (Zepbound) and Novo Nordisk's semaglutide (Wegovy) expanded indications and market access sharply cutting U.S. obesity rates.​

FDA approvals for oral GLP-1s like semaglutide 25mg (obesity) and others (e.g., orforglipron) are expected in late 2025/early 2026.​

Generic versions of liraglutide (Saxenda) entered the US market in 2025, enhancing affordability.​

Emerging oral dual and triple agonists such as retatrutide and VK2735 display up to 20-24% weight loss in Phase II/III trials, rivaling bariatric surgery.

Forecast Projection:

The global Anti-obesity Drugs market is set to witness strong growth from 2025 to 2032. After maintaining steady momentum in 2024, the market is expected to accelerate as key industry players implement strategic initiatives to boost adoption. Companies that adapt to these emerging trends will be well-positioned to capture new opportunities and enhance their revenue potential throughout the forecast period.

Market Intelligence Research Process:

The Anti-obesity Drugs Market Report by DataM Intelligence offers a comprehensive analysis built on a mix of primary and secondary research. It explores key factors driving the industry, including government policies, market trends, competitive landscape, technological advancements, and upcoming innovations. This in-depth study uncovers both growth opportunities and potential challenges, helping businesses navigate market fluctuations and make data-driven decisions for sustainable success.

Buy Now & Get 30% OFF - (Grab 50% OFF on 2+ reports) @ https://www.datamintelligence.com/buy-now-page?report=anti-obesity-drugs-market?kb

Key Segmentations:

By Mechanism of Action: (Peripherally Acting Drugs, Centrally Acting Drugs)

By Drug Type: (Prescription Drugs, OTC Drugs)

By Route of Administration: (Oral, Intravenous/Subcutaneous)

By Distribution Channel: (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)

Get Customization in the report as per your requirements: https://datamintelligence.com/customize/anti-obesity-drugs-market?kb

FAQ's

Q1: How large is the Anti-obesity Drugs Market?

Ans: The Anti-obesity Drugs Market size was valued at US$ 2.5 billion in 2022 and is projected to grow to US$ 43.7 billion by 2030.

Q2: How quickly is the Anti-obesity Drugs Market expanding?

Ans: The Anti-obesity Drugs Market is forecasted to grow at a CAGR of 45.5% between 2025 and 2032, showing Annual growth momentum

Q3: Which regions are dominating the Anti-obesity Drugs Market and which are fastest-growing?

Ans: North America dominating the Anti-obesity Drugs market.

FDA Approvals

FDA approved Zepbound (tirzepatide) and expanded use of Wegovy (semaglutide) for chronic weight management including patients with comorbid diabetes.​

FDA also cleared Teva's generic liraglutide (Saxenda) for weight loss therapy.​

New guidance emphasizes requirement for ≥5% placebo-adjusted weight loss efficacy and lifestyle co-interventions in clinical trials.

Have any Query We Will Provide in Detailed @ https://www.datamintelligence.com/enquiry/anti-obesity-drugs-market?kb

Reimbursement

Medicare and Medicaid expanded coverage for obesity drugs with negotiated pricing capped at $245/month for injectables and lower for orals, improving patient access.​

Private insurers increasingly cover anti-obesity drugs, with some "step edits" guiding cost-effective formulary positioning.​

Coverage disparities remain an issue in emerging markets due to pricing and infrastructure.

Get 2-Day Free Trial + 50% OFF DataM Subscription@ https://www.datamintelligence.com/reports-subscription?kb

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com
Linkedin: https://www.linkedin.com/company/datam-intelligence/
Twitter: https://x.com/DataM_Research

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.